Condition: Multiple Myeloma (MM) · Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Double Hit Lymphoma · Sponsor: IDP Discovery Pharma S.L.
The main aims of this 2-part study are: * Phase I: To determine the maximum tolerated dose (MTD) and the recommended phase 2 dose (RP2D) of IDP-121 in patients with multiple myeloma (MM), diffuse large B cell lymphoma not otherwise specified (DLBCL-NOS), high-grade B cell lymphoma with double or triple hit rearrangement (HGBL-DH/TH) and HGBL-NOS, and chronic lymphocytic leukemia (CLL). * Phase II: To evaluate the overall response rate (ORR), duration of response (DoR), time to progression (TTP), progression-free survival (PFS), event-free survival (EFS) and Overall survival (OS), in patients with MM, DLBCL-NOS, HGBL-DH/TH, HGBL-NOS or CLL treated with IDP-121 at the recommended Phase 2 Dose (RP2D).
This description comes directly from the study's public registry record.
David Molina, PhD · +34669616086 · d.molina@idp-pharma.com
Laura Nevola, PhD · +34622540215 · l.nevola@idp-pharma.com
Always discuss trial participation with your own doctor first.
| Hospital Universitario Marques de Valdecilla | Santander, Cantabria, Spain | Recruiting |
| Hospital Universitario de Salamanca | Salamanca, Castille and León, Spain | Recruiting |
| Hospital Universitari Vall d'hebron | Barcelona, Spain | Recruiting |
| Hospital Durán i Reynals - ICO L´Hospitalet | Barcelona, Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid, Spain | Recruiting |
| Hospital Universitario La Paz | Madrid, Spain | Recruiting |
| Hospital Universitario Puerta de Hierro | Madrid, Spain | Recruiting |
| Hospital Clínico Universitario Virgen de la Arrixaca | Murcia, Spain | Recruiting |
| Hospital Universitario Virgen del Rocio | Seville, Spain | Recruiting |
| Hospital de Clinico Universitario de Valencia | Valencia, Spain | Recruiting |
| Hospital Universitario Miguel Servet | Zaragoza, Spain | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05908409